EE430 Evaluating Cost Benefits of Subcutaneous vs. Intravenous Trastuzumab/Pertuzumab in HER2-Positive Early Breast Cancer Patients: From Qatari Healthcare Perspective
Abstract
Authors
Laila Shafei Shereen ElAzzazy Amir Nounou Anas Hamad